Introduction
Infiltrating ductal adenocarcinoma of the pancreas is a highly invasive and extremely lethal neoplasm, which currently ranks as the fifth leading cause of cancer death in the United States (Jemal et al., 2003) . Despite the fact that surgical resection remains the only hope for longterm survival in patients with pancreatic cancer (Sohn et al., 2000) , most (B85%) patients are found to be unresectable at presentation due to extensive local invasion and/or metastatic disease (DiMagno et al., 1999) . The molecular mechanisms responsible for the biological aggressiveness of pancreatic cancer have not been fully understood.
Cancer invasion and metastasis is a complex mechanism that includes a variety of cellular processes, among which the proteolytic degradation of extracellular matrix has been considered one of the most critical events. The matrix degradation can be promoted by the imbalance between proteolytic enzymes (proteases) and their inhibitors (Westermarck and Kahari, 1999; Brinckerhoff and Matrisian, 2002) . Extensive studies focusing on the two major proteolytic systems, matrix metalloproteinases and plasminogen activators, have established the contribution of inappropriate activation of these proteases to invasion and metastasis of most solid tumors including pancreatic cancer (Paciucci et al., 1998; Ellenrieder et al., 1999; Sato et al., 2003b) . On the other hand, little is known about the role of protease inhibitors, notably tissue factor pathway inhibitors, in pancreatic cancer progression.
Tissue factor pathway inhibitor 2 (TFPI-2) is a Kunitz-type serine proteinase inhibitor that acts against a wide range of proteases, including plasmin, trypsin, chymotrypsin, cathepsin G, and plasma kallikrein (Miyagi et al., 1994; Sprecher et al., 1994; Rao et al., 1995; Petersen et al., 1996) . Based on its broad and potent inhibitory effects on protease activities, TFPI-2 is thought to protect the matrix from degradation thereby counteracting tumor invasion and metastasis (Rao et al., 1998; Izumi et al., 2000; Jin et al., 2001; Konduri et al., 2001) . Recently, aberrant methylation has been suggested as a possible mechanism for loss of TFPI-2 expression in a subset of tumor cell lines (Hube et al., 2003; Konduri et al., 2003; Rao et al., 2003) . We have used a microarray-based screening approach to identify novel genes affected by aberrant DNA methylation in pancreatic cancer (Sato et al., 2003a) . Using this approach, we have identified the TFPI-2 as a gene that is highly upregulated by treatment of pancreatic cancer cells with the DNA methyltransferase inhibitor and/or histone deacetylase inhibitor. These findings led us to hypothesize that this gene could be a target for epigenetic silencing in pancreatic cancer. To test this hypothesis, we investigated the expression and methylation patterns of the TFPI-2 gene in invasive pancreatic adenocarcinomas and precursors IPMNs (intraductal papillary mucinous neoplasms) of the pancreas. We also explored the mechanism for the TFPI-2 gene inactivation in a panel of pancreatic cancer xenografts by a combination of DNA methylation, loss of heterozygosity (LOH), and gene mutation analyses. Finally, we characterized functional effects of restoring TFPI-2 in pancreatic cancer cells lacking TFPI-2 expression.
Results

Identification of TFPI-2 as a gene induced by epigenetic modifying agents in pancreatic cancer cells
Using microarrays, we previously identified a substantial number of genes that were markedly induced in pancreatic cancer cells by treatment with 5Aza-dC and/ or TSA (Sato et al., 2003a) . Among the genes identified, the TFPI-2 gene was of particular interest because it encodes for a broad-spectrum serine proteinase inhibitor that may play an important role in tumor invasion and metastasis. We therefore determined the expression and methylation patterns of TFPI-2 in pancreatic cancer.
Gene expression profiling of four pancreatic cancer cell lines (AsPC1, Hs766 T, MiaPaCa2, and Panc1) by oligonucleotide microarray and by RT-PCR analysis demonstrated that TFPI-2 mRNA expression was undetectable in all the four cell lines, but robustly induced after combined treatment with 5Aza-dC and TSA (Figure 1 ). Although the expression response of individual cell lines to each drug alone was variable, these findings suggest that TFPI-2 is transcriptionally regulated, at least in part, by epigenetic mechanisms involving DNA methylation and histone deacetylation.
Expression patterns of TFPI-2 in normal pancreas, pancreatic cancer cell lines, and primary pancreatic ductal neoplasms Next, we examined the expression of TFPI-2 mRNA in normal pancreas and in a larger panel of pancreatic cancer cell lines by RT-PCR. We found abundant mRNA expression of TFPI-2 in all of the seven normal pancreatic tissues analysed (Figure 2a) , which is consistent with previous studies demonstrating that TFPI-2 is ubiquitously expressed in a wide variety of tissues including the pancreas (Miyagi et al., 1994; Wojtukiewicz et al., 2003) . By contrast, the TFPI-2 expression was undetectable in 65% (11 of 17) of pancreatic cancer cell lines (Figure 2a) , and the relative TFPI-2 expression level (normalized by GAPDH expression) in pancreatic cancer cell lines was significantly lower than that in normal pancreatic tissues (0.18 versus 1.64, P ¼ 0.004). For comparison, we also analysed the expression of TFPI-1, another family member of tissue factor pathway inhibitors. Unlike the expression pattern of TFPI-2, the TFPI-1 transcript was readily detectable in all the pancreatic cancer cell lines tested, albeit at reduced levels in some (Figure 2a ). These findings imply that TFPI-2 may be a specific target for gene silencing in pancreatic cancer.
To assess whether the silencing of TFPI-2 observed in established cell lines occurs in primary tumors, we utilized oligonucleotide microarrays to determine quantitatively the expression level of TFPI-2 in a panel of 12 IPMNs, known precursor lesions of pancreatic adenocarcinoma. The gene expression analysis revealed that TFPI-2 mRNA was highly expressed in normal pancreatic ductal epithelium and in primary fibroblasts Epigenetic inactivation of TFPI-2 in pancreatic cancer N Sato et al derived from chronic pancreatitis tissue, whereas the TFPI-2 transcript was absent in 83% (10 of 12) of IPMNs and was detected only at very low levels in the remaining two cases (Figure 2b ). The average intensity for TFPI-2 expression in all the 12 IPMNs was B50-fold underexpressed relative to five control samples from normal pancreatic ductal epithelium. RT-PCR analysis on the corresponding samples showed concordant results and confirmed the frequent loss of TFPI-2 expression in IPMNs (Figure 2c ). Together, these results provide evidence that TFPI-2 expression is silenced in primary pancreatic ductal neoplasms (IPMNs) as well as in pancreatic cancer cell lines.
Methylation analysis of TFPI-2 in pancreatic cancer cell lines
To elucidate a potential mechanism that underlies the TFPI-2 gene silencing in pancreatic cancer, we evaluated the methylation status of TFPI-2 in pancreatic cancer and normal pancreas. The TFPI-2 gene harbors a CpGrich sequence spanning over 1 kb from the promoter region to exon 2 (%CG ¼ 59.5%, Obs/Exp. CpG ¼ 0.75, and length ¼ 1095 bp), which meets the stringent criteria of a CpG island (Takai and Jones, 2002) (Figure 3a) . We first used MSP to determine the methylation status of the region around the transcription start site in normal pancreas and pancreatic cancer cell lines. We found that TFPI-2 was unmethylated in a panel of 13 normal pancreatic tissues, including five normal pancreatic ductal epithelial samples obtained by laser-capture microdissection (Figure 3b ). By contrast, aberrant methylation of TFPI-2 was identified in 14 (82%) of 17 pancreatic cancer cell lines (Figure 3b ). Bisulfite genomic sequencing analysis was also performed on normal pancreatic tissues and several pancreatic cancer to À13 with respect to the translation start site) in the TFPI-2 CpG island. Consistent with the results from MSP, the majority of CpG sites analysed were completely unmethylated in normal pancreatic tissues, whereas they were predominantly to completely methylated in the pancreatic cancer cell lines tested ( Figure 3c ). The cell lines that harbored methylated TFPI-2 expressed little or no mRNA, demonstrating the expected inverse correlation between methylation and expression of TFPI-2. One cell line (Panc1) that lacked the TFPI-2 expression was found to have only slight methylation, suggesting that other mechanism(s), such as histone deacetylation, may play a predominant role in the gene silencing in this cell line. This was supported by our finding of marked induction of TFPI-2 expression in Panc1 cells treated with TSA alone.
Relationship between methylation status of TFPI-2 and gene induction in response to the phorbol ester (PMA)
To confirm that DNA methylation is a primary mechanism for the silencing of TFPI-2, six pancreatic cancer cell lines with differing methylation status were exposed to phorbol 12-myristate-13-acetate (PMA). PMA is known to stimulate the TFPI-2 promoter activity through the ERK/MAPK pathway, and a potential AP-1 binding site (at nucleotide position À156) appears to be involved in this PMA-mediated TFPI-2 induction (Konduri et al., 2002; Kast et al., 2003) . Exposure to PMA augmented the TFPI-2 mRNA expression in a cell line (CFPAC1) with unmethylated TFPI-2 and in two cell lines (BxPC3 and Su8686) with partially methylated TFPI-2 (Figure 4a ). PMA stimulation, however, failed to induce the TFPI-2 expression in three cell lines (AsPC1, Capan1, and Capan2) that harbored fully methylated TFPI-2 ( Figure 4a ). We then determined the effect of loss of DNA methylation on the PMA-mediated TFPI-2 induction by treating AsPC1 with 5Aza-dC and/or TSA. Although PMA treatment alone was unable to induce TFPI-2 mRNA expression in AsPC1, pretreatment with 5Aza-dC restored the response to PMA and synergistically increased the expression after PMA exposure ( Figure 4b ). TSA pretreatment, however, was unable to restore the response to PMA. Thus, these data further support the role of DNA methylation in the transcriptional repression of inducible as well as basal TFPI-2 expression in certain pancreatic cancer cell lines.
Methylation, loss of heterozygosity (LOH), and mutation analyses of TFPI-2 in pancreatic cancer xenografts
Considering that the TFPI-2 gene is located at chromosome 7q22 (Miyagi et al., 1996) and that LOH at 7q has been detected in pancreatic cancer (Hahn et al., 1995; Iacobuzio-Donahue et al., 2004) , we wondered if this gene is specifically targeted for inactivation through genetic as well as epigenetic means. To test this, we analysed a panel of pancreatic cancer xenografts for TFPI-2 methylation status and correlated it with the results of LOH data at the TFPI-2 gene locus (7q22 region) determined by two microsatellite markers (D7S821 and D7S1799). Using MSP, we detected aberrant methylation of TFPI-2 in 31 (82%) of 38 xenografts analysed, of which 16 (52%) were completely methylated at TFPI-2 (Figure 5a ). For 27 xenografts in which both LOH and TFPI-2 methylation analyses were performed, allelic loss at the TFPI-2 locus was identified in four (16%) of 25 informative cases. Two of the four xenografts with LOH displayed complete methylation of TFPI-2, raising the possibility of two-hit inactivation through LOH and methylation. The other two xenografts with LOH harbored unmethylated TFPI-2. Among the 21 xenografts showing allelic retention, 10 xenografts (48%) demonstrated complete methylation of TFPI-2, implying extensive methylation involving both of the alleles, whereas the remaining 11 xenografts were partially methylated (n ¼ 8) or unmethylated (n ¼ 3) for TFPI-2.
To determine if an additional genetic mechanism is involved in the loss of TFPI-2 expression in pancreatic cancer, we screened for somatic mutations in the TFPI-2 gene in a subset of 15 xenografts (including two xenografts with LOH and unmethylated TFPI-2 and RT-PCR analysis of TFPI-2 in AsPC1, where TFPI-2 is methylation-silenced, after treatment with solvent (control), PMA alone, TSA plus PMA, 5Aza-dC alone, and 5Aza-dC plus PMA Epigenetic inactivation of TFPI-2 in pancreatic cancer N Sato et al 13 xenografts with partial methylation). Direct sequencing of the entire coding sequence and exon/intron boundaries revealed no mutations in all the xenografts examined. In two xenografts showing partial methylation, however, a single nucleotide change from G to A (GAG to GAA) was found at codon 107 of exon 3. This nucleotide change would not result in amino-acid change and is likely to be a naturally occurring polymorphism.
Aberrant methylation of TFPI-2 in primary pancreatic neoplasms
To test whether the aberrant methylation of TFPI-2 detected in pancreatic cancer cell lines and xenografts are also present in primary tumors, we expanded our methylation analysis to a large series of 102 surgically resected pancreatic adenocarcinomas. Overall, aberrant methylation of TFPI-2 was detected in 70% (71/102) of primary pancreatic carcinomas (Figure 5b ). Among the clinicopathological correlations, the mean age of patients with TFPI-2 methylation in their primary cancers was significantly higher than in those patients without methylation (69 versus 61 years; P ¼ 0.0009). There was no association between other clinicopathological variables (including gender, the maximum diameter of the tumor, histological differentiation (well, moderately, or poorly differentiated), and the presence of lymph node metastasis) and TFPI-2 methylation.
We also examined the methylation status of TFPI-2 in 32 IPMNs of different histological grades, and the prevalence of aberrant methylation was 59% (19/32) in these neoplasms (Figure 5c ). To determine the correlation between TFPI-2 methylation and progression of IPMNs, we divided IPMNs into two groups according to histological grade: those classified as adenoma or borderline (low-grade IPMNs; n ¼ 12) and those classified as in situ carcinoma (high-grade IPMNs; n ¼ 20). Strikingly, aberrant methylation of TFPI-2 was detected at a significantly higher frequency in high-grade IPMNs than in low-grade IPMNs (85 versus 17%; P ¼ 0.0002) (Figure 5d ). These results demonstrate that aberrant methylation of TFPI-2 is a common event in primary pancreatic cancers, and suggest that this epigenetic alteration contributes to the malignant progression of pancreatic ductal neoplasms.
Detection of methylated TFPI-2 in pancreatic juice samples from patients with pancreatic cancer
To evaluate the diagnostic potential of TFPI-2, we tested whether aberrant methylation of TFPI-2 is detectable in pancreatic juice samples collected from patients with pancreatic cancer. Using MSP, we analysed the TFPI-2 methylation status in a total of 41 pancreatic juice samples including 30 from patients with pancreatic adenocarcinoma and 11 from patients with benign pancreatic disorders. Aberrant methylation of TFPI-2 was detected in 17 (57%) of the 30 juice samples from patients with pancreatic cancer, whereas juice samples from 11 patients with benign diseases displayed only unmethylated templates (P ¼ 0.0009) (Figure 5e ). These results suggest that detection of methylated TFPI-2 in pancreatic juice samples could be used as an aid in the diagnosis of pancreatic cancer.
Effects of restored TFPI-2 expression on the malignant behaviors of pancreatic cancer cells that lack TFPI-2 expression
The frequent silencing of the TFPI-2 gene in association with aberrant hypermethylation raises an important question regarding its biological relevance in pancreatic cancer progression. To answer this question, we stably transfected TFPI-2 into nonexpressing pancreatic cancer cells and evaluated their malignant phenotypes. We first investigated the effect of TFPI-2 expression on the colony-formation ability of AsPC1 cells, where TFPI-2 is methylation-silenced, in the presence of G418. Transfection with TFPI-2 significantly suppressed the number of surviving and expanding colonies by B80% compared with transfection with empty vector (P ¼ 0.0001; Figure 6a ), indicating that TFPI-2 has a growth-suppressing function. To further characterize the functional effects of restoring TFPI-2 on the biological behavior (notably invasiveness) of pancreatic cancer cells, we stably transfected TFPI-2 into another pancreatic cancer cell line (Panc1) that also lacks TFPI-2 expression and that is highly invasive in in vitro assays. A stable transfectant expressing TFPI-2 at a level equivalent to that of normal pancreas (Figure 6b ) was expanded and analysed for its malignant behavior, as assessed by in vitro cell proliferation assay, cell migration assay, and Matrigel invasion assay. Panc1 cells stably transfected with TFPI-2 showed marked decrease in their proliferation (B60% reduction, Po0.0001, Figure 6c ), migration (B55% reduction, Po0.0001, Figure 6d ), and invasiveness (B67% reduction, Po0.0001, Figure 6e ) as compared with an empty-vector transfected control. These effects were consistent through at least three independent experiments for each assay. Together, these results suggest the potent inhibitory effects of TFPI-2 on the growth and invasion of pancreatic cancer cells where TFPI-2 is silenced, thus highlighting the important role of TFPI-2 inactivation in pancreatic cancer progression.
Discussion
The proteolytic degradation of the extracellular matrix, one of the key events in the process of tumor invasion and metastasis, depends on the balance between matrixdegrading proteases and their inhibitors. Although the role for increased protease activity in the invasive behavior of cancer cells has been established (Westermarck and Kahari, 1999; Brinckerhoff and Matrisian, 2002) , investigation of the biological significance of protease inhibitors in pancreatic cancer progression remains less well understood. In the present study, we analysed the expression, regulation, and functional significance of TFPI-2, one of the major protease inhibitors previously implicated in the coagulation pathways and matrix proteolysis, in pancreatic cancer. Our major findings are (1) TFPI-2 is frequently silenced in pancreatic cancer cell lines and IPMNs; (2) loss of TFPI-2 expression is associated with aberrant methylation of its promoter CpG island; and (3) restored expression of TFPI-2 in nonexpressing pancreatic cancer cells results in marked suppression in their proliferation, migration, and invasive potential in vitro. These findings suggest TFPI-2 as a growth-, and invasion-suppressor gene that is commonly inactivated through epigenetic mechanisms in pancreatic cancer.
Previous studies have found that TFPI-2 is downregulated in certain types of human malignant tumors (Izumi et al., 2000; Rao et al., 2001) , but the regulatory mechanism of TFPI-2 is not fully understood. Here we provide evidence that TFPI-2 is transcriptionally regulated, at least in part, by DNA methylation. Importantly, complete methylation of TFPI-2 was closely linked to its transcriptional repression that was not released by stimulation with PMA, a PMA known to enhance the TFPI-2 promoter activity (Konduri et al., 2002; Kast et al., 2003) . Aberrant methylation of TFPI-2 has been recently described as a possible mechanism for gene silencing in a limited number of cancer cell lines (Hube et al., 2003; Konduri et al., 2003; Rao et al., 2003) ; however, the prevalence of such methylation in primary tumors has not been explored. By analyzing a large number of xenografted tumors and surgically resected pancreatic adenocarcinomas, we were able to confirm the aberrant methylation of TFPI-2 in the majority of primary pancreatic cancers. Our data also demonstrated that TFPI-2 is much more likely to be methylated in high-grade compared to low-grade IPMNs, suggesting that TFPI-2 silencing is a late event in IPMN development and contributes to the malignant progression of pancreatic ductal neoplasms.
The mechanism responsible for TFPI-2 methylation in pancreatic neoplasms is not known. Although several lines of evidence suggest that aberrant DNA hypermethylation in cancer is maintained by DNA methyltransferase activity (Rhee et al., 2002; Robert et al., 2003) , the mechanism by which such methylation occurs at specific loci during carcinogenesis remains unclear. Recent studies have suggested that methylation changes in cancer may occur, at least in some cases, as a consequence of genetic or other events that alter the transcriptional activities of affected promoters (Di Croce et al., 2002) , and that DNA methylation may serve to lock in rather than initiate the gene silencing (Bachman et al., 2003) . Thus, hypermethylation of TFPI-2 could be a result of gene silencing induced by activation of oncogene(s) or changes in transcription factors. In fact, a previous study has demonstrated that overexpression of an activated form of human H-ras oncogene in MRC-5 fibroblasts results in downregulation of the TFPI-2 expression (Izumi et al., 2000) . However, ras oncogene activation is unlikely to explain the loss of TFPI-2 expression because several pancreatic cancer cell lines known to harbor K-ras mutations (such as CFPAC1 and Su8686) (Kern, 2000) express TFPI-2 mRNA.
Our present findings may have important clinical implications. First, the high incidence of TFPI-2 hypermethylation in pancreatic cancer and the absence of such methylation in normal pancreatic ductal epithelium suggests its potential utility as a diagnostic marker (Fukushima et al., 2003) . Using the highly sensitive MSP assay, we were able to detect aberrantly methylated TFPI-2 in 57% of pancreatic juice samples from patients with pancreatic cancer, but not in juice samples from patients with benign pancreatic disorders. Although it appears that the detection of a single methylated gene is not sufficiently sensitive, we and other investigators demonstrated that the detection and quantification of aberrant methylation of a combination of multiple genes can increase the sensitivity and provide a powerful tool for cancer diagnosis (Evron et al., 2001; Harden et al., 2003; Sato et al., 2003a) . The TFPI-2 gene should be, thus, added to the list of candidate diagnostic markers for pancreatic cancer.
Second, because restored expression of TFPI-2 showed potent tumor-suppressor activities in pancreatic cancer cells lacking its expression, restoration of the loss of TFPI-2 function in pancreatic cancers has the potential to delay the growth and invasion of these cancers. Although previous studies have focused on the effects of TFPI-2 on the invasive properties of tumor cells (Rao et al., 1998; Izumi et al., 2000; Jin et al., 2001; Konduri et al., 2001) , we demonstrate that in addition to its effects on migration and invasion, TFPI-2 inhibits the in vitro colony formation and proliferation of pancreatic cancer cells. The mechanism for the TFPI-2-mediated growth suppression is unknown, but recent evidence suggested that expression of TFPI-2 induces apoptosis in glioma cells . More recently, it has been shown that HT-1080 fibrosarcoma cells expressing inactive R24Q TFPI-2 form tumors of 2-3 times larger in athymic mice compared to wild-type TFPI-2 expressing counterparts (Chand et al., 2004) . Interestingly, TFPI-2 has been reported to stimulate the growth of vascular smooth muscle cells (Shinoda et al., 1999) and retinal pigment epithelial cells (Tanaka et al., 2004) , implying cell type-specific role of TFPI-2 in cellular proliferation. These diverse biological effects of TFPI-2 on various cell types as well as the therapeutic potential of restoring TFPI-2 function in pancreatic cancer cells should be carefully evaluated in future studies.
In conclusion, we identified TFPI-2 as a specific target for aberrant CpG island hypermethylation in pancreatic cancer, and inactivation of this gene may contribute to the malignant behavior of pancreatic cancer cells.
Materials and methods
Cell lines and tissue samples
In total, 18 human pancreatic cancer cell lines were used in the present study. Pancreatic cancer xenografts were established from surgically resected primary pancreatic carcinomas (Hahn et al., 1995) , and 38 xenografts were randomly selected for this analysis. Primary tissue samples from a total of 102 pancreatic ductal adenocarcinomas, 12 IPMNs, and eight normal pancreata were collected from patients undergoing pancreatic resection at the Johns Hopkins Hospital. Normal pancreatic duct epithelial cells were selectively microdissected from the resected pancreata of five patients using a Pixcell II LCM system (Arcturus Engineering Inc., Mountain View, CA, USA). Pancreatic juice samples were collected intraoperatively from 41 patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma (n ¼ 30) and other pancreatic disorders including chronic pancreatitis (n ¼ 5), islet cell tumor (n ¼ 3), and serous cystadenoma (n ¼ 3).
Drug treatment
We treated 4 pancreatic cancer cell lines with 5-aza-2 0 -deoxycytidine (5Aza-dC) and/or trichostatin A (TSA) as previously described (Sato et al., 2003a) . Six pancreatic cancer cell lines were treated with PMA (1 mM) or solvent (DMSO) alone for 5 h. For combined treatment with PMA and 5Aza-dC or TSA, cells were initially exposed to 5Aza-dC (1 mM) for 3 days or TSA (0.5 or 1 mM) for 24 h, and then treated with PMA (1 mM) for 5 h.
Oligonucleotide array hybridization and data analysis
Global gene expression profiling was performed using oligonucleotide microarrays (Human Genome U133A, Affymetrix, Santa Clara, CA, USA) as described previously (Sato et al., 2003a) .
Reverse transcription-polymerase chain reaction (RT-PCR)
In total, 4 mg of total RNA was reverse-transcribed using Superscript II (Invitrogen). RT-PCR was performed using primers specific either for TFPI-1 (5 0 -AAC AAG AAA AGC CAG ATT TCT G-3 0 (forward) and 5 0 -TTC GGA CCA TCT TCA CAA ATG-3 0 (reverse)) or TFPI-2 (5 0 -CCA GAT GAA Epigenetic inactivation of TFPI-2 in pancreatic cancer N Sato et al GCT ACT TGT ATG-3 0 (forward) and 5 0 -GCA CAT GCA CGT TTG CAA TC-3 0 (reverse)). The PCR condition was as follows: 951C for 5 min; then 25-30 cycles of 951C for 20 s, 601C (for TFPI-1) or 631C (for TFPI-2) for 20 s, and 721C for 30 s; and a final extension of 4 min at 721C. For semiquantitative analysis, the RT-PCR was performed with primers to amplify GAPDH in duplex reactions. The range of linear amplification for each gene and the GAPDH gene was examined with serial PCR cycles, and the optimal PCR cycles were determined. The relative intensity of TFPI-1 or TFPI-2 mRNA expression was measured by densitometry and then corrected for variable RNA recovery using the corresponding GAPDH mRNA measurement as a surrogate for total mRNA.
Methylation-specific PCR (MSP) and bisulfite sequencing analysis
Genomic DNA was treated with sodium bisulfite (Sigma), purified, and subjected to MSP as described previously (Herman et al., 1996) . Briefly, bisulfite-treated DNA (1 mg) was amplified using primers specific for either the methylated or for the unmethylated DNA under the conditions as follows: 951C for 5 min; 35 cycles of 951C for 20 s, 581C for 20 s, and 721C for 30 s; and a final extension of 4 min at 721C. Primer sequences were GGA TGT TTG TTT TGT ATA AAG TG (forward) and AAA CAT CCA AAA AAA CAC CTA AC (reverse) for unmethylated reactions (89 bp), and TTT CGT ATA AAG CGG GTA TTC (forward) and ACG ACC CGC TAA ACA AAA CG (reverse) for methylated reactions (95 bp). For bisulfite sequencing analysis, a 344-bp fragment of the 5 0 region of the TFPI-2 gene was amplified using the primers: AGG TAG GTT TAA TTT TTT AAT TTG (forward) and TAC CTA TTA ACT CCT AAA CAA C (reverse). PCR conditions were as follows: 951C for 5 min; 45 cycles of 951C for 20 s, 601C for 20 s, and 721C for 30 s; and a final extension of 4 min at 721C. After incubation with exonuclease I and shrimp alkaline phosphatase (USB, Cleveland, OH, USA), the PCR products were sequenced using the SequiTherm Excel II cycle sequencing kit (Epicentre Technologies, Madison, WI, USA).
Loss of heterozygosity (LOH) analysis
A comprehensive LOH analysis was performed in a panel of pancreatic cancer xenografts using multiple markers as described in a separate study (Iacobuzio-Donahue et al., 2004) .
Direct sequencing
Exons 1-5 of the TFPI-2 gene were amplified from genomic DNA using five primer sets (primer sequences are available upon request). PCR products were treated with exonuclease I and shrimp alkaline phosphatase, and were subjected to cyclesequencing.
TFPI-2 expression vector and transfection
The TFPI-2 expression vector was constructed by inserting the entire coding region of the human TFPI-2 cDNA (Genbank No. D29992) into a mammalian expression vector, pBos-Citeneo (Miyagi et al., 1994) . Cells were seeded at a density of 1 Â 10 5 cells/well in six-well plates. After overnight incubation, the TFPI-2 expression vector (0.5 mg/ml per well) or empty pBos-Cite-neo vector (0.5 mg/ml per well) was transfected into the cells using Lipofectamine 2000 (Invitrogen) . To obtain stable transfectants, cells were selected with G418 (500 mg/ml) for 2-3 weeks, and single-cell colonies were isolated, expanded, and used for subsequent experiments.
Colony formation assay
Cells were transfected either with TFPI-2 expression vector or with empty vector as described above. At 48 h after transfection, cells (2 Â 10 4 ) were re-plated in 100-mm dishes and cultured for 3 weeks in complete medium containing G418. Surviving colonies were counted in triplicate plates after staining with crystal violet.
Cell proliferation assay
Cells were plated at a density of 2 Â 10 4 cells/well onto six-well plates and cultured in complete medium containing G418 for 72 h. The total numbers of cells were counted in six independent wells.
In vitro cell migration and invasion assay
Cell culture inserts (24-well type, 8-mm pore size) were coated (for invasion assay) or uncoated (for migration assay) with 20 mg of Matrigel (BD Biosciences). Cells suspended in serum-free medium (RPMI 1640 with 0.1% BSA) were seeded into the upper chamber (500 ml/well) at a density of 3 Â 10 4 cells/ml (for migration assay) or 6 Â 10 4 cells/ml (for invasion assay). The lower chambers were filled with RPMI 1640 (1% FBS). After 24-h incubation, cells attached to the upper side of the filter were removed, and the filters were fixed and stained with hematoxylin and eosin. At this time point, there was no difference in the total number of cells (proliferation rate) between groups in the serumfree medium. The number of cells that had migrated to the undersurface of the membrane was counted in randomly selected five microscopic fields in each sample.
Statistical analysis
Statistical analysis was performed using Fisher's exact probability test or unpaired Student's t-test (two-tailed). Po0.05 was considered significant. Abbreviations TFPI-2, tissue factor pathway inhibitor 2; 5Aza-dC, 5-aza-2 0 -deoxycytidine; TSA, trichostatin A; RT-PCR, reverse transcription-PCR; MSP, methylation-specific PCR; IPMN, intraductal papillary mucinous neoplasm; PMA, phorbol 12-myristate-13-acetate.
